USD 14,351M DARZALEX sales in 2025 underpin Genmab (GMAB) royalties
Rhea-AI Filing Summary
Genmab A/S reported that worldwide 2025 net trade sales of the cancer medicine DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO formulation, were USD 14,351 million as reported by Johnson & Johnson. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world. Genmab receives royalties on all worldwide net sales of both the intravenous and subcutaneous products under its exclusive license agreement with Johnson & Johnson. The filing also reiterates that Genmab is a biotechnology company focused on antibody-based medicines, with multiple approved therapies and a late-stage clinical pipeline.
Positive
- None.
Negative
- None.
Insights
DARZALEX 2025 sales of USD 14.35B reinforce a major royalty stream for Genmab.
The key disclosure is that worldwide 2025 net trade sales of DARZALEX, including DARZALEX FASPRO, reached USD 14,351 million, with USD 8,266 million generated in the U.S. and USD 6,085 million in the rest of the world. Because Genmab licenses daratumumab to Johnson & Johnson and receives royalties on global net sales, this large revenue base underpins an important partnered income stream.
The announcement does not provide royalty rates or year-on-year comparisons, so the magnitude of any growth versus prior periods is not detailed in this excerpt. Still, a double‑digit billion‑dollar sales level for a single product highlights DARZALEX as a core commercial asset in Genmab’s portfolio, alongside its broader antibody platform and late-stage pipeline.
Subsequent financial reports for the period covering 2025 will show how these DARZALEX sales translate into reported royalty revenue and profit contribution for Genmab, and how this interacts with investment in its wholly owned clinical programs.
FORM 6-K
(Exact name of Registrant as specified in its charter)
(Address of principal executive offices)
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated January 21, 2026 | ||||
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson & Johnson.
FAQ
What 2025 DARZALEX sales did Genmab (GMAB) report in this 6-K?
Genmab reported that worldwide 2025 net trade sales of DARZALEX, including the subcutaneous DARZALEX FASPRO formulation, were USD 14,351 million as reported by Johnson & Johnson.
How were 2025 DARZALEX net sales for Genmab (GMAB) split between the U.S. and rest of world?
Of the total 2025 net trade sales of USD 14,351 million, USD 8,266 million came from the U.S. and USD 6,085 million from the rest of the world.
How does Genmab (GMAB) benefit financially from DARZALEX sales?
Genmab receives royalties on worldwide net sales of DARZALEX, both intravenous and subcutaneous products, under an exclusive worldwide license granted to Johnson & Johnson to develop, manufacture and commercialize daratumumab.
Which partner reports DARZALEX sales referenced by Genmab (GMAB)?
The 2025 net trade sales figures for DARZALEX are those reported by Johnson & Johnson, through its legal entity Janssen Biotech, Inc.
What kind of company is Genmab (GMAB) according to this filing?
Genmab is described as an international biotechnology company focused on improving the lives of people with cancer and other serious diseases through innovative antibody medicines, including bispecific antibodies, ADCs and other next‑generation modalities.
Does Genmab (GMAB) mention other approved medicines or pipeline assets?
Genmab states that its science powers eight approved antibody medicines and that it is advancing a strong late-stage clinical pipeline, including wholly owned programs, aimed at delivering transformative medicines.